☆ 4.6 Article

Low Pre-Chemoradiotherapy Pan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas

JOURNAL OF INFLAMMATION RESEARCH (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma

T. Gambichler et al.

Summary: The purpose of this study was to determine whether the pan-immune-inflammation value (PIV) of patients with Merkel cell carcinoma (MCC) at primary diagnosis differs from controls and whether it is associated with disease stage and outcome. The results showed that the PIV of MCC patients was significantly increased compared to controls and that a higher PIV was associated with MCC recurrence.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

Xinru Chen et al.

Summary: This study evaluated the prognostic power of Pan-Immune-Inflammation Value (PIV) as a predictor of survival outcomes in patients with ALK-positive advanced NSCLC who received first-line ALK tyrosine kinase inhibitors (TKIs). The results showed that PIV was an independent prognostic factor for both progression-free survival (PFS) and overall survival (OS), and it can serve as a comprehensive and convenient predictor for clinical outcomes in these patients.

TRANSLATIONAL ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy

Martin Perez-Martelo et al.

Summary: The study validates the prognostic significance of baseline PIV in patients with mCRC receiving first-line standard chemotherapy in a real-world scenario, suggesting the potential utility of PIV monitoring to anticipate disease progression among patients who achieve initial disease control.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Review Oncology

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

Deniz Can Guven et al.

Summary: This study reviewed the association between the pan-immune-inflammation value (PIV) and overall survival or progression-free survival in cancer patients. The results showed that higher PIV levels were consistently associated with adverse prognosis in various clinical scenarios, except for patients treated with chemotherapy or non-metastatic disease. PIV could be a potential prognostic biomarker in cancer, but further research is needed.

CANCERS (2022)

添加到收藏夹

Article Medicine, General & Internal

A New Prognostic Index in Young Breast Cancer Patients

Hacer Demir et al.

Summary: This study evaluated the prognostic role of pan immune-inflammation value (PIV) in young breast cancer patients. The results showed that patients in the high PIV group had a more advanced stage and were younger. Although the survival was worse in the high PIV group, the difference was not statistically significant. Therefore, PIV may be another prognostic marker, but further validation in larger, multi-center studies is needed.

JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN (2022)

添加到收藏夹

Article Oncology

PILE: a candidate prognostic score in cancer patients treated with immunotherapy

D. C. Guven et al.

Summary: This study evaluated a candidate scoring system based on PIV as a prognostic biomarker in patients treated with ICIs. The results showed that patients with higher PIV had significantly decreased overall survival.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Radiotherapy for locally advanced pancreatic ductal adenocarcinoma

Elizabeth J. Buss et al.

Summary: This review summarizes the expanding role of radiotherapy in the management of locally advanced, unresectable pancreatic cancer. Higher, ablative doses of radiation and advancements in technology have been shown to improve patient survival rates.

SEMINARS IN ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann et al.

Summary: The study compared the efficacy and safety of two multidrug induction chemotherapy regimens for locally advanced pancreatic cancer and found that nab-paclitaxel plus gemcitabine is similarly active and safe as nab-paclitaxel plus gemcitabine followed by FOLFIRINOX. However, further evidence is needed to determine whether this translates into improved overall survival for patients.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Immunology

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

Ran Zeng et al.

Summary: The study found that high PIV and PILE scores were correlated with worse clinical outcomes in ES-SCLC patients treated with anti-PD-1/PD-L1 inhibitor combined with chemotherapy, suggesting that these factors could be useful in identifying patients unlikely to benefit from such therapy.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

Francesca Ligorio et al.

Summary: The Pan-Immune-Inflammatory Value (PIV) in peripheral blood may serve as a new and powerful predictor of overall survival in HER2+ advanced breast cancer patients treated with first-line trastuzumab-pertuzumab-containing biochemotherapy, potentially improving prognostic stratification in this patient population.

CANCERS (2021)

添加到收藏夹

Article Cell Biology

Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients

Yifang Shui et al.

Aging-US (2021)

添加到收藏夹

Article Oncology

The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

Francesca Corti et al.

Summary: The Pan-Immune-Inflammation Value (PIV) proved to be a strong predictor of outcomes in MSI-high mCRC patients receiving ICIs, and both high baseline PIV and early PIV increase were associated with poorer overall survival and progression-free survival. Early PIV increase was identified as an independent predictor of clinical benefit.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy

Giovanni Fuca et al.

Summary: The study revealed that high PIV is associated with poor clinical outcomes in patients with metastatic melanoma, including lower overall survival and progression-free survival, as well as primary resistance to both immunotherapy and targeted therapy.

TARGETED ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy

Ahmet Bilgehan Sahin et al.

Summary: The study indicates that PIV is a better predictor for predicting the efficacy of neoadjuvant chemotherapy and survival in breast cancer patients, outperforming NLR, MLR, and PLR.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Immunology

The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy

Erkan Topkan et al.

Summary: The study evaluated a novel pancreas cancer prognostic index (PCPI) by combining CA 19-9 and SIRI in locally advanced pancreas adenocarcinoma patients, dividing them into three subgroups with distinct survival outcomes.

JOURNAL OF INFLAMMATION RESEARCH (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection

Gerd Jomrich et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2020)

添加到收藏夹

Article Oncology

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fuca et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Article

Prognostic and predictive factors in pancreatic cancer

Emanuela Dell’Aquila et al.

Oncotarget (2020)

添加到收藏夹

Review Oncology

Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

Aaron J. Grossberg et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy

Erkan Topkan et al.

GASTROENTEROLOGY RESEARCH AND PRACTICE (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity

Andrea Padoan et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Article Oncology

Lymphocyte-to-Monocyte Ratio and Prognostic Nutritional Index Predict Poor Prognosis in Patients on Chemotherapy for Unresectable Pancreatic Cancer

Tetsunosuke Shimizu et al.

ANTICANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy

Erkan Topkan et al.

CANCER MANAGEMENT AND RESEARCH (2019)

添加到收藏夹

Article Surgery

Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?

Jin He et al.

ANNALS OF SURGERY (2018)

添加到收藏夹

Article Medicine, General & Internal

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial

Pascal Hammel et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Phosphatidylinositol 3-Kinase A Link Between Inflammation and Pancreatic Cancer

Chiara Birtolo et al.

PANCREAS (2016)

添加到收藏夹

Article Oncology

Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer

Y. Geng et al.

EJSO (2015)

添加到收藏夹

Article Medicine, General & Internal

Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer

H. L. Martin et al.

INTERNAL MEDICINE JOURNAL (2014)

添加到收藏夹

Review Oncology

Exploiting inflammation for therapeutic gain in pancreatic cancer

C. W. Steele et al.

BRITISH JOURNAL OF CANCER (2013)

添加到收藏夹

Article Oncology

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer

M. Stotz et al.

BRITISH JOURNAL OF CANCER (2013)

添加到收藏夹

Review Pharmacology & Pharmacy

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy

Anna Tamburrino et al.

FRONTIERS IN PHARMACOLOGY (2013)

添加到收藏夹

Article Oncology

Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 ≤90 U/mL and Comparison to the CONKO-001 Trial

Adam C. Berger et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hallmarks of Cancer: The Next Generation

Douglas Hanahan et al.

CELL (2011)

添加到收藏夹

Article Cell Biology

Pancreatic cancers require autophagy for tumor growth

Shenghong Yang et al.

GENES & DEVELOPMENT (2011)

添加到收藏夹

Article Oncology

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression

Christopher H. Crane et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Surgery

Preoperative Neutrophil-to-Lymphocyte Ratio (NLR) is Associated with Reduced Disease-free Survival Following Curative Resection of Pancreatic Adenocarcinoma

G. Garcea et al.

WORLD JOURNAL OF SURGERY (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection

Sara Raimondi et al.

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2010)

添加到收藏夹

Article Oncology

Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review

Florence Huguet et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Oncology

DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

Christine A. Iacobuzio-Donahue et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer-related inflammation

Alberto Mantovani et al.

NATURE (2008)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial

Helmut Oettle et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.